enGene Holdings Inc. (NASDAQ:ENGN) CEO Ronald Harold Wilfred Cooper Buys 10,000 Shares

enGene Holdings Inc. (NASDAQ:ENGN) CEO Ronald Harold Wilfred Cooper bought 10,000 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was acquired at an average cost of $5.70 per share, for a total transaction of $57,000.00. Following the completion of the purchase, the chief executive officer now directly owns 10,000 shares in the company, valued at $57,000. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

enGene Stock Performance

NASDAQ ENGN opened at $6.61 on Tuesday. The business’s 50-day moving average price is $6.96 and its 200 day moving average price is $10.66. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm has a market cap of $291.94 million, a P/E ratio of -3.84 and a beta of -0.68. enGene Holdings Inc. has a 52-week low of $4.42 and a 52-week high of $43.00.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.05. On average, equities research analysts expect that enGene Holdings Inc. will post -1.64 earnings per share for the current year.

Analysts Set New Price Targets

ENGN has been the topic of a number of recent analyst reports. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price objective on shares of enGene in a report on Tuesday, September 24th. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research note on Wednesday, September 11th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $33.67.

Hedge Funds Weigh In On enGene

Several hedge funds have recently bought and sold shares of ENGN. Altitude Crest Partners Inc. purchased a new stake in enGene during the first quarter worth $2,039,000. SR One Capital Management LP acquired a new position in shares of enGene during the 2nd quarter worth $4,715,000. Omega Fund Management LLC purchased a new stake in shares of enGene in the fourth quarter valued at about $10,441,000. Logos Global Management LP lifted its stake in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in shares of enGene during the 1st quarter worth about $17,095,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.